Hypothalamo-, Pituitary-, Adrenal Axis Dysfunction in Subarachnoid Hemorrhage

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00614887

Acronym

SAHENDO

Enrollment

Registered

2008-02-13

Start date

2006-03-31

Completion date

2008-01-31

Last updated

2023-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Aneurysm, Subarachnoid Hemorrhage

Keywords

Subarachnoid hemorrhage, Pituitary gland, Adrenal gland

Brief summary

Subarachnoid haemorrhage (SAH) may cause damage to the hypotalamo-pituitary-adrenal axis (HPA) thus disturbing the hormonal response of these structures. The aim of our study is to characterize the function of HPA-axis acutely and over time up to three months in patients with SAH.

Detailed description

The hypotalamo-pituitary-adrenal (HPA)-axis may be affected in SAH by temporary or permanent damage to the hypothalamus and/or pituitary gland. Also surgery or endovascular treatment of a ruptured intracranial aneurysm may affect the hormonal response of the HPA-axis. Some data suggest a high incidence of delayed endocrine abnormalities in patients with SAH but only little data exists on the acute endocrine abnormalities in this disease. We will study the pituitary-adrenal hormone levels in patients with acute aneurysmal SAH and patients admitted for elective cranial aneurysm surgery will serve as a control population. We will use serum free cortisol calculation and total cortisol measurements as well as adrenocorticotrophic hormone (ACTH) stimulation test in assessing the responsiveness of the adrenal gland to exogenous ACTH. The hormone levels will be measured repeatedly during the first seven days after SAH and once at three months.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

SAH-group: * \>age 18, * Subarachnoid hemorrhage due to an cerebral aneurysm Control group: * Age \>18 * Admitted for elective primary cerebral aneurysm surgery

Exclusion criteria

SAH group: * Any corticoid treatment (also inhaled) * Usage of etomidate before study entry or during the study period * Exact bleeding day unknown * Previous history of SAH or more than three days of current bleeding * Previous aneurysm surgery or embolization * Traumatic SAH * Known pituitary insufficiency and moribund state of the patient * Refusement of the patient control group: * Any corticoid treatment (also inhaled) * Usage of etomidate before study entry or during the study period * Previous history of SAH or cerebral aneurym surgery or embolization * Admitted for elective aneurysm embolization * Known pituitary insufficiency * Refusement of the patienT

Countries

Finland

Outcome results